Indolent Lymphoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Indolent Lymphoma – Pipeline Review, H2 2016’, provides an overview of the Indolent Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Indolent Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Indolent Lymphoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma

The report reviews pipeline therapeutics for Indolent Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Indolent Lymphoma therapeutics and enlists all their major and minor projects

The report assesses Indolent Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Indolent Lymphoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Affimed GmbH

Altor BioScience Corporation

Amgen Inc.

Astellas Pharma Inc.

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Juno Therapeutics Inc.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

MorphoSys AG

Novartis AG

Seattle Genetics, Inc.

Trillium Therapeutics Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Indolent Lymphoma Overview 10

Therapeutics Development 11

Pipeline Products for Indolent Lymphoma - Overview 11

Indolent Lymphoma - Therapeutics under Development by Companies 12

Indolent Lymphoma - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Indolent Lymphoma - Products under Development by Companies 16

Indolent Lymphoma - Companies Involved in Therapeutics Development 18

AbbVie Inc 18

Affimed GmbH 19

Altor BioScience Corporation 20

Amgen Inc. 21

Astellas Pharma Inc. 22

Bayer AG 23

Boehringer Ingelheim GmbH 24

Bristol-Myers Squibb Company 25

Celgene Corporation 26

Eli Lilly and Company 27

F. Hoffmann-La Roche Ltd. 28

Gilead Sciences, Inc. 29

Incyte Corporation 30

Infinity Pharmaceuticals, Inc. 31

Juno Therapeutics Inc. 32

MedImmune, LLC 33

Merck & Co., Inc. 34

Merck KGaA 35

Millennium Pharmaceuticals Inc 36

MorphoSys AG 37

Novartis AG 38

Seattle Genetics, Inc. 39

Trillium Therapeutics Inc. 40

Indolent Lymphoma - Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Combination Products 42

Assessment by Target 43

Assessment by Mechanism of Action 46

Assessment by Route of Administration 49

Assessment by Molecule Type 51

Drug Profiles 53

AFM-11 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

ALT-803 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

bendamustine hydrochloride - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

BI-836826 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

blinatumomab - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

BMS-986016 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

BTH-1677 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

CC-122 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

copanlisib hydrochloride - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

DI-B4 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

duvelisib - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

entospletinib - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

ibrutinib - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

INCB-40093 - Drug Profile 127

Product Description 127

Mechanism Of Action 127

R&D Progress 127

INCB-50465 - Drug Profile 128

Product Description 128

Mechanism Of Action 128

R&D Progress 128

inebilizumab - Drug Profile 129

Product Description 129

Mechanism Of Action 129

R&D Progress 129

inebilizumab + MEDI-0680 - Drug Profile 131

Product Description 131

Mechanism Of Action 131

R&D Progress 131

itacitinib adipate - Drug Profile 132

Product Description 132

Mechanism Of Action 132

R&D Progress 132

JCAR-014 - Drug Profile 135

Product Description 135

Mechanism Of Action 135

R&D Progress 135

JCAR-015 - Drug Profile 138

Product Description 138

Mechanism Of Action 138

R&D Progress 138

JCAR-017 - Drug Profile 143

Product Description 143

Mechanism Of Action 143

R&D Progress 143

lenalidomide - Drug Profile 146

Product Description 146

Mechanism Of Action 146

R&D Progress 146

LY-3023414 - Drug Profile 160

Product Description 160

Mechanism Of Action 160

R&D Progress 160

MOR-208 - Drug Profile 162

Product Description 162

Mechanism Of Action 162

R&D Progress 162

obinutuzumab - Drug Profile 167

Product Description 167

Mechanism Of Action 167

R&D Progress 167

ofatumumab - Drug Profile 174

Product Description 174

Mechanism Of Action 174

R&D Progress 174

SEA-CD40 - Drug Profile 182

Product Description 182

Mechanism Of Action 182

R&D Progress 182

TAK-659 - Drug Profile 183

Product Description 183

Mechanism Of Action 183

R&D Progress 183

TTI-621 - Drug Profile 184

Product Description 184

Mechanism Of Action 184

R&D Progress 184

venetoclax - Drug Profile 187

Product Description 187

Mechanism Of Action 187

R&D Progress 187

vorinostat - Drug Profile 196

Product Description 196

Mechanism Of Action 196

R&D Progress 196

Indolent Lymphoma - Dormant Projects 200

Indolent Lymphoma - Discontinued Products 202

Indolent Lymphoma - Product Development Milestones 203

Featured News & Press Releases 203

Jun 04, 2016: Juno Therapeutics To present Data on JCAR017 at the 52nd Annual Meeting of the American Society 203

Nov 30, 2015: New Data from Bayer’s Portfolio in Oncology to be Presented at ASH 2015 203

Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting 203

Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 204

Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 204

Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R 206

Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 207

Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) 208

Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH 210

Appendix 212

Methodology 212

Coverage 212

Secondary Research 212

Primary Research 212

Expert Panel Validation 212

Contact Us 212

Disclaimer 213

List of Tables

List of Tables

Number of Products under Development for Indolent Lymphoma, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Indolent Lymphoma – Pipeline by AbbVie Inc, H2 2016 18

Indolent Lymphoma – Pipeline by Affimed GmbH , H2 2016 19

Indolent Lymphoma – Pipeline by Altor BioScience Corporation, H2 2016 20

Indolent Lymphoma – Pipeline by Amgen Inc., H2 2016 21

Indolent Lymphoma – Pipeline by Astellas Pharma Inc., H2 2016 22

Indolent Lymphoma – Pipeline by Bayer AG, H2 2016 23

Indolent Lymphoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 24

Indolent Lymphoma – Pipeline by Bristol-Myers Squibb Company, H2 2016 25

Indolent Lymphoma – Pipeline by Celgene Corporation, H2 2016 26

Indolent Lymphoma – Pipeline by Eli Lilly and Company, H2 2016 27

Indolent Lymphoma – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 28

Indolent Lymphoma – Pipeline by Gilead Sciences, Inc., H2 2016 29

Indolent Lymphoma – Pipeline by Incyte Corporation, H2 2016 30

Indolent Lymphoma – Pipeline by Infinity Pharmaceuticals, Inc., H2 2016 31

Indolent Lymphoma – Pipeline by Juno Therapeutics Inc., H2 2016 32

Indolent Lymphoma – Pipeline by MedImmune, LLC, H2 2016 33

Indolent Lymphoma – Pipeline by Merck & Co., Inc., H2 2016 34

Indolent Lymphoma – Pipeline by Merck KGaA, H2 2016 35

Indolent Lymphoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 36

Indolent Lymphoma – Pipeline by MorphoSys AG, H2 2016 37

Indolent Lymphoma – Pipeline by Novartis AG, H2 2016 38

Indolent Lymphoma – Pipeline by Seattle Genetics, Inc., H2 2016 39

Indolent Lymphoma – Pipeline by Trillium Therapeutics Inc., H2 2016 40

Assessment by Monotherapy Products, H2 2016 41

Assessment by Combination Products, H2 2016 42

Number of Products by Stage and Target, H2 2016 44

Number of Products by Stage and Mechanism of Action, H2 2016 47

Number of Products by Stage and Route of Administration, H2 2016 50

Number of Products by Stage and Molecule Type, H2 2016 52

Indolent Lymphoma – Dormant Projects, H2 2016 200

Indolent Lymphoma – Dormant Projects (Contd..1), H2 2016 201

Indolent Lymphoma – Discontinued Products, H2 2016 202

List of Figures

List of Figures

Number of Products under Development for Indolent Lymphoma, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 15

Assessment by Monotherapy Products, H2 2016 41

Number of Products by Top 10 Targets, H2 2016 43

Number of Products by Stage and Top 10 Targets, H2 2016 43

Number of Products by Top 10 Mechanism of Actions, H2 2016 46

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 46

Number of Products by Routes of Administration, H2 2016 49

Number of Products by Stage and Routes of Administration, H2 2016 49

Number of Products by Molecule Types, H2 2016 51

Number of Products by Stage and Molecule Types, H2 2016 51


Discounts available for multiple purchases.
+44 20 7947 2745

Saved reports